Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements
24 Enero 2023 - 3:05PM
Guardion Health Sciences, Inc (“Guardion” or the “Company”)
(NASDAQ: GHSI) announced today that it has received confirmation
from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained
compliance with the minimum bid price requirement of $1.00 per
share under Nasdaq Listing Rule 5550(a)(2) and currently meets all
other applicable criteria for continued listing.
On January 25, 2022, Nasdaq notified Guardion
that its common stock failed to maintain a minimum bid price of
$1.00 over the previous 30 consecutive trading days as required by
the Listing Rules of Nasdaq. Subsequently, by letter dated January
24, 2023, Nasdaq has determined that for the last 10 consecutive
trading days, from January 9, 2023 through January 23, 2023, the
closing bid price of Guardion’s common stock has been $1.00 per
share or greater, and the Company has therefore regained compliance
with Listing Rule 5550(a)(2), and this matter is now closed.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI),
is a clinical nutrition company that offers a portfolio of
science-based, clinically supported products designed to support
the health needs of consumers, healthcare professionals and
providers and their patients. The Company’s combination of
expertise and scientifically supported products is the foundation
of Guardion’s growing position within the clinical nutrition
marketplace. Information and risk factors with respect to Guardion
and its business may be obtained in the Company’s filings with the
SEC at www.sec.gov.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These
forward-looking statements contain information about our
expectations, beliefs, plans or intentions regarding our product
development and commercialization efforts, research and development
efforts, business, financial condition, results of operations,
strategies or prospects, and other similar matters. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans,” “hopes” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing.
These statements are based on management’s
current expectations and assumptions about future events, which are
inherently subject to uncertainties, risks and changes in
circumstances that are difficult to predict, and involve unknown
risks and uncertainties that may individually or materially impact
the matters discussed herein for a variety of reasons that are
outside the control of the Company, including, but not limited to,
the Company’s ability to raise sufficient financing to implement
its business plan, the impact of the Company’s exploration of
strategic alternatives, the integration of new management team
members, the implementation of new financial, management,
accounting and business software systems, the integration of
possible acquisition targets, the impact of the Covid-19 pandemic,
supply chain disruptions, inflation and a potential recession on
the Company’s business, operations and the economy in general, the
Company’s ability to successfully develop and commercialize its
proprietary products and technologies, and the Company’s ability to
maintain compliance with Nasdaq’s listing requirements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, as actual results
could differ materially from those described in the forward-looking
statements contained herein. Readers are urged to read the risk
factors set forth in the Company’s filings with the SEC, which are
available at the SEC’s website (www.sec.gov). The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:CORE IRScott
Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Guardion Health Sciences (NASDAQ:GHSI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024